• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[2015年中国癌症死亡率的流行病学分析]

[Epidemiological analysis on mortality of cancer in China, 2015].

作者信息

Lan L, Zhao F, Cai Y, Wu R X, Meng Q

机构信息

Department of Epidemiology and Health Statistics, West China School of Public Health, Sichuan University, Chengdu 610041, China.

National Health and Family Planning Commission, Beijing 100044, China.

出版信息

Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Jan 10;39(1):32-34. doi: 10.3760/cma.j.issn.0254-6450.2018.01.006.

DOI:10.3760/cma.j.issn.0254-6450.2018.01.006
PMID:29374891
Abstract

To understand the distribution of cancer deaths in China in 2015 and provide reference for the prevention and control of cancer. Based on the results of Global Burden of Disease 2015, the cancer death distributions in different age groups, sex groups, provinces or by different malignant tumor in Chinese were described. The age-standardized mortality rate of cancer was 159.01/100 000 in China in 2015. The mortality rate was highest in age group ≥70 years (1 102.73/100 000), and lowest in age group 5-14 years (5.40/100 000). The mortality rate in males was 2.15 times higher than that in females. The first 5 provinces with high cancer mortality rate were Anhui, Qinghai, Sichuan, Guangxi and Henan. Lung cancer, liver cancer, stomach cancer, esophageal cancer and colorectal cancer ranked 1-5 in term of mortality rate. The cancer mortality differed with age, gender, area and different malignant tumors, suggesting the necessity to develop targeted prevention and control strategies.

摘要

了解2015年中国癌症死亡情况,为癌症防控提供参考。基于《2015年全球疾病负担》结果,描述了中国不同年龄组、性别组、省份或不同恶性肿瘤的癌症死亡分布情况。2015年中国癌症年龄标准化死亡率为159.01/10万。死亡率在≥70岁年龄组最高(1102.73/10万),在5-14岁年龄组最低(5.40/10万)。男性死亡率是女性的2.15倍。癌症死亡率排名前5的省份是安徽、青海、四川、广西和河南。肺癌、肝癌、胃癌、食管癌和结直肠癌死亡率排名1-5位。癌症死亡率因年龄、性别、地区和不同恶性肿瘤而异,提示制定针对性防控策略的必要性。

相似文献

1
[Epidemiological analysis on mortality of cancer in China, 2015].[2015年中国癌症死亡率的流行病学分析]
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Jan 10;39(1):32-34. doi: 10.3760/cma.j.issn.0254-6450.2018.01.006.
2
[Report of Cancer Incidence and Mortality in China, 2014].《2014年中国癌症发病与死亡报告》
Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002.
3
[Analysis of cancer incidence and mortality in elderly population in China, 2013].[2013年中国老年人群癌症发病率与死亡率分析]
Zhonghua Zhong Liu Za Zhi. 2017 Jan 23;39(1):60-66. doi: 10.3760/cma.j.issn.0253-3766.2017.01.012.
4
[Analysis of cancer incidence and mortality in Henan province, 2009].[2009年河南省癌症发病率与死亡率分析]
Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Jul;47(7):597-602.
5
[Estimation of cancer incidence and mortality in China in 2004-2005].[2004 - 2005年中国癌症发病率与死亡率估算]
Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):664-8.
6
[Incidence and mortality of cancers appeared in the Hebei provincial cancer registry system in 2011].2011年河北省癌症登记系统中出现的癌症发病率和死亡率
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Aug;36(8):846-51.
7
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
8
[Deaths attributed to ambient air pollution in China between 2006 and 2016].2006年至2016年间中国归因于环境空气污染的死亡情况
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Nov 10;39(11):1449-1453. doi: 10.3760/cma.j.issn.0254-6450.2018.11.006.
9
Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China.21世纪初中国广西原发性肝癌的流行病学分析
Chin J Cancer. 2010 May;29(5):545-50. doi: 10.5732/cjc.009.10510.
10
[Mortality attributable to high body mass index in Chinese people aged 15 or over, in 1990 and 2013].1990年及2013年中国15岁及以上人群中归因于高体重指数的死亡率
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Sep 6;50(9):776-781. doi: 10.3760/cma.j.issn.0253-9624.2016.09.006.

引用本文的文献

1
Potential role of hypobaric hypoxia environment in treating pan-cancer.低压缺氧环境在治疗泛癌中的潜在作用。
Sci Rep. 2025 Apr 15;15(1):12942. doi: 10.1038/s41598-024-84561-3.
2
Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer.信迪利单抗治疗晚期非小细胞肺癌疗效与安全性的Meta分析
Oncol Lett. 2022 Oct 12;24(6):425. doi: 10.3892/ol.2022.13545. eCollection 2022 Dec.
3
Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer.胃癌患者乙型肝炎病毒感染的血清学和分子特征。
Front Cell Infect Microbiol. 2022 May 3;12:894836. doi: 10.3389/fcimb.2022.894836. eCollection 2022.
4
Effect of trimodal pre-rehabilitation on the rehabilitation of patients with gastrointestinal tumors in the perioperative period.三联术前康复对胃肠道肿瘤患者围手术期康复的影响。
Am J Transl Res. 2022 Feb 15;14(2):967-978. eCollection 2022.
5
Efficacy of radiofrequency ablation versus laparoscopic liver resection for hepatocellular carcinoma in China: a comprehensive meta-analysis.中国射频消融与腹腔镜肝切除治疗肝细胞癌的疗效:一项综合荟萃分析。
Wideochir Inne Tech Maloinwazyjne. 2021 Sep;16(3):455-471. doi: 10.5114/wiitm.2021.105377. Epub 2021 Apr 14.
6
Fibrinogen-to-Albumin Ratio is Associated with All-Cause Mortality in Cancer Patients.纤维蛋白原与白蛋白比值与癌症患者的全因死亡率相关。
Int J Gen Med. 2021 Aug 27;14:4867-4875. doi: 10.2147/IJGM.S322735. eCollection 2021.
7
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.细胞因子诱导的杀伤细胞/树突状细胞及细胞因子诱导的杀伤细胞免疫疗法治疗食管癌的荟萃分析
Medicine (Baltimore). 2021 Apr 2;100(13):e24519. doi: 10.1097/MD.0000000000024519.
8
Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma.评估循环肿瘤细胞对晚期肝细胞癌患者经动脉化疗栓塞治疗预后的预测能力。
Medicine (Baltimore). 2021 Jan 8;100(1):e24060. doi: 10.1097/MD.0000000000024060.
9
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade.了解食管癌:未来十年的挑战与机遇
Front Oncol. 2020 Sep 10;10:1727. doi: 10.3389/fonc.2020.01727. eCollection 2020.
10
[Over-expression of miR-144 inhibits invasion of liver cancer SMMC-7721 cells by suppressing TLR/MyD88 pathway].[miR-144过表达通过抑制TLR/MyD88通路抑制肝癌SMMC-7721细胞侵袭]
Nan Fang Yi Ke Da Xue Xue Bao. 2020 May 30;40(5):765-771. doi: 10.12122/j.issn.1673-4254.2020.05.25.